Coherus Oncology, Inc.
CHRS
$1.22
$0.065.17%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 12.84% | 34.94% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 12.84% | 34.94% | |||
| Cost of Revenue | 9.60% | 27.97% | |||
| Gross Profit | 14.45% | 38.68% | |||
| SG&A Expenses | -12.32% | 0.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.47% | 5.10% | |||
| Operating Income | 7.15% | -0.11% | |||
| Income Before Tax | 0.77% | 5.35% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 0.77% | 5.35% | |||
| Earnings from Discontinued Operations | -97.38% | 3,836.00% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -111.93% | 626.38% | |||
| EBIT | 7.15% | -0.11% | |||
| EBITDA | 7.20% | -0.18% | |||
| EPS Basic | -111.92% | 625.33% | |||
| Normalized Basic EPS | 5.59% | 5.51% | |||
| EPS Diluted | -111.92% | 625.33% | |||
| Normalized Diluted EPS | 5.59% | 5.51% | |||
| Average Basic Shares Outstanding | 0.13% | 0.19% | |||
| Average Diluted Shares Outstanding | 0.13% | 0.19% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||